Micronized tanaproget, compositions, and methods of preparing the same
The present invention provides compositions, desirably pharmaceutical compositions, containing micronized tanaproget. The compositions can also contain microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, magnesium stearate, micronized edetate calcium disodium hydrous, and micronized sodium thiosulfate pentahydrate. The compositions are useful in contraception and hormone replacement therapy and in the treatment and/or prevention of uterine myometrial fibroids, benign prostatic hypertrophy, benign and malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, endometriosis, polycystic ovary syndrome, and carcinomas and adenocarcinomas of the pituitary, endometrium, kidney, ovary, breast, colon, and prostate and other hormone-dependent tumors, and in the preparation of medicaments useful therefor. Additional uses include stimulation of food intake.
1. A kit comprising a pharmaceutical composition comprising an intragranulation comprising micronized tanaproget or a pharmaceutically acceptable salt thereof, microcrystalline cellulose, croscarmellose sodium, anhydrous lactose, magnesium stearate, micronized edetate calcium disodium hydrous, and micronized sodium thiosulfate pentahydrate.
2. The kit according to claim 1 , wherein said pharmaceutical composition further comprises extragranular croscarmellose sodium and extragranular magnesium stearate.
3. The kit according to claim 2 , wherein said extragranular croscarmellose sodium comprises about 2% wt/wt of said pharmaceutical composition.
4. The kit according to claim 2 , wherein said extragranular magnesium stearate comprises about 0.19% of said pharmaceutical composition.
5. The kit according to claim 1 , wherein the particles of said micronized tanaproget are less than about 10 μm.
6. The kit according to claim 1 , wherein the particles of said micronized sodium thiosulfate pentahydrate are less than about 31 μm.
7. The kit according to claim 1 , wherein the particles of said micronized sodium edetate calcium disodium hydrous are less than about 35 μm.
8. The kit according to claim 1 , wherein said pharmaceutical composition degrades less than about 3% over a period of greater than 1 month at temperatures at or greater than about 25° C. and a relative humidity at or greater than about 60%.
9. The kit according to claim 1 , wherein said tanaproget comprises about 0.15% to about 0.50% wt/wt of said pharmaceutical composition.
10. The kit according to claim 1 , wherein said tanaproget comprises about 0.15% wt/wt of said pharmaceutical composition.
11. The kit according to claim 1 , wherein said tanaproget comprises about 0.23% wt/wt of said pharmaceutical composition.
12. The kit according to claim 1 , wherein said tanaproget comprises about 0.31% wt/wt of said pharmaceutical composition.
13. The kit according to claim 1 , wherein said tanaproget comprises about 0.5% wt/wt of said pharmaceutical composition.
14. The kit according to claim 1 , wherein said intragranular microcrystalline cellulose comprises about 40% wt/wt of said pharmaceutical composition.
15. The kit according to claim 1 , wherein said intragranular croscarmellose sodium comprises about 2% wt/wt of said pharmaceutical composition.
16. The kit according to claim 1 , wherein said intragranular magnesium stearate comprises about 0.19% wt/wt of said pharmaceutical composition.
17. The kit according to claim 1 , wherein said intragranular anhydrous lactose comprises about 54% to about 55% wt/wt of said pharmaceutical composition.
18. The kit according to claim 1 , wherein said intragranular micronized edetate calcium disodium hydrous comprises about 0.10% wt/wt of said pharmaceutical composition.
19. The kit according to claim 1 , wherein said intragranular micronized sodium thiosulfate pentahydrate comprises about 0.5% wt/wt of said pharmaceutical composition.
20. The kit according to claim 1 , wherein the particles of said pharmaceutical composition are less than about 100 μm.
21. The kit according to claim 1 , further comprising one or more progestational agent, estrogen, or selective estrogen receptor modulator.
22. The kit according to claim 1 , comprising a single phase of a daily dosage of said pharmaceutical composition over a 21-day, 28-day, 30-day, or 31-day cycle.
23. The kit according to claim 1 , comprising a single phase of a daily dosage of said pharmaceutical composition over the first 21 days of a 28-day, 30-day, or 31-day cycle.
24. The kit according to claim 1 , comprising a single phase of a daily dosage of said pharmaceutical composition over the first 28 days of a 30-day or 31-day cycle.
25. The kit according to claim 1 , comprising a single combined phase of a daily dosage of said pharmaceutical composition and a progestational agent;
wherein the daily dosage units total 28.
26. The kit according to claim 1 , comprising 21 daily dosage units of a single combined phase of said pharmaceutical composition and a progestational agent;
wherein the daily dosage units total 28, 30, or 31.
27. The kit according to claim 1 , comprising 28 daily dosage units of a single combined phase of said pharmaceutical composition and a progestational agent;
wherein the daily dosage units total 30 or 31.
28. The kit according to claim 1 , comprising:
(i) a first phase of from 14 to 28 daily dosage units of said pharmaceutical composition;
(ii) a second phase of from 1 to 11 daily dosage units of a progestational agent; and
(iii) daily dosage units of an orally and pharmaceutically acceptable placebo;
wherein the daily dosage units total 28.
29. The kit according to claim 1 , comprising:
(i) a first phase of from 14 to 21 daily dosage units of said pharmaceutical composition; and
(ii) a second phase of from 1 to 11 daily dosage units of a progestational agent; and
(iii) daily dosage units of an orally and pharmaceutically acceptable placebo;
wherein the daily dosage units total 28.
30. The kit according to claim 1 , comprising:
(i) a first phase of from 18 to 21 daily dosage units of said pharmaceutical composition; and
(ii) a second phase of from 1 to 7 daily dose units of a progestational agent; and
(iii) daily dosage units of an orally and pharmaceutically acceptable placebo;
wherein the daily dosage units total 28.
31. The kit according to claim 1 , comprising:
(i) a first phase of 21 daily dosage units of said pharmaceutical composition;
(ii) a second phase of 3 daily dosage units for days 22 to 24 of a progestational agent;
(iii) a third phase of 4 daily dosage units for days 25 to 28 of a pharmaceutically acceptable placebo;
wherein the daily dosage units total 28.
32. The kit according to claim 1 , comprising:
(i) a first phase of from 14 to 21 daily dosage units of a progestational agent equal in progestational activity to about 35 to about 150 μg levonorgestrel; and
(ii) a second phase of from 1 to 11 daily dosage units of said pharmaceutical composition; and
(iii) daily dosage units of an orally and pharmaceutically acceptable placebo;
wherein the daily dosage units total 28.
33. The kit according to claim 1 , comprising:
(i) a first phase of from 14 to 21 daily dosage units of a progestational agent equal in progestational activity to about 35 to about 100 μg levonorgestrel; and
(ii) a second phase of from 1 to 11 daily dosage units of said pharmaceutical composition; and
(iii) daily dosage units of an orally and pharmaceutically acceptable placebo;
wherein the daily dosage units total 28.
34. The kit according to claim 1 , which is designed for treating or preventing benign prostatic hypertrophy, benign neoplastic disease, malignant neoplastic disease, dysfunctional bleeding, uterine leiomyomata, polycystic ovary syndrome, carcinomas, or adenocarcinomas.
35. A kit comprising a pharmaceutical composition comprising about 0.15% wt/wt micronized tanaproget or a pharmaceutically acceptable salt thereof, about 40% wt/wt microcrystalline cellulose, about 4% wt/wt croscarmellose sodium, about 54.87% wt/wt anhydrous lactose, about 0.38% wt/wt magnesium stearate, about 0.1% wt/wt micronized edetate calcium disodium hydrous, and about 0.5% wt/wt micronized sodium thiosulfate pentahydrate.
36. A kit comprising a pharmaceutical composition comprising about 0.23% wt/wt micronized tanaproget or a pharmaceutically acceptable salt thereof, about 40% wt/wt microcrystalline cellulose, about 4% wt/wt croscarmellose sodium, about 54.79% wt/wt anhydrous lactose, about 0.38% wt/wt magnesium stearate, about 0.1% wt/wt micronized edetate calcium disodium hydrous, and about 0.5% wt/wt micronized sodium thiosulfate pentahydrate.
37. A kit comprising a pharmaceutical composition comprising about 0.31% wt/wt micronized tanaproget or a pharmaceutically acceptable salt thereof, about 40% wt/wt microcrystalline cellulose, about 4% wt/wt croscarmellose sodium, about 54.71% wt/wt anhydrous lactose, about 0.38% wt/wt magnesium stearate, about 0.1% wt/wt micronized edetate calcium disodium hydrous, and about 0.5% wt/wt micronized sodium thiosulfate pentahydrate.
38. A kit comprising a pharmaceutical composition comprising about 0.46% wt/wt micronized tanaproget or a pharmaceutically acceptable salt thereof, about 40% wt/wt microcrystalline cellulose, about 4% wt/wt croscarmellose sodium, about 54.56% wt/wt anhydrous lactose, about 0.38% wt/wt magnesium stearate, about 0.1% wt/wt micronized edetate calcium disodium hydrous, and about 0.5% wt/wt micronized sodium thiosulfate pentahydrate.